Cambridge, MA, United States of America

Omar Ahmad

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Blueprint Medicines Corporation. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Omar Ahmad. Retrieved from https://idiyas.com/inventor/omar-ahmad-1newye2e

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Omar Ahmad - Innovator in Cancer Treatment

Introduction

Omar Ahmad is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development.

Latest Patents

Omar Ahmad holds 1 patent related to EGFR inhibitors. This patent provides a compound represented by structural formula (I-0) or a pharmaceutically acceptable salt thereof, which is useful for treating cancer.

Career Highlights

Omar Ahmad is currently associated with Blueprint Medicines Corporation, where he continues to advance his research in oncology. His work focuses on developing targeted therapies that can improve patient outcomes.

Collaborations

Some of his notable coworkers include John Emmerson Campbell and Thomas A Dineen, who collaborate with him on various projects within the company.

Conclusion

Omar Ahmad's contributions to cancer treatment through his patent on EGFR inhibitors highlight his role as an innovator in the medical field. His ongoing work at Blueprint Medicines Corporation continues to pave the way for advancements in cancer therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…